2IARC.GLOBOCAN 2012:Estimated cancer incidence,mortality and prevalence worldwide in 2012[EB/OL].[2014-02-28].http://globocan.iare.fr/Default.aspx.
3赫捷,陈万青.2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:12-25.
4IMS Health.The Global Use of Medicines:Outlook Through 2016[EB/OL].[2014-02-28].http://www.imshealth.com/portal/site/ims/menuitem.d248e29c86589c9c30e81 c033208c22a/vgnextoid=4d47d 1822e678310VgnVCM 10000076192ca2RCRD&vgnextchannel=437879d7f269e210VgnVCM10000071812ca2RCRD&vgnextfmt=default.
5Scherer FM.The link between gross profitability and pharmaceutical R&D spending[J].Health Aff(Millwood),2001,20(5):216-220.
2Eric Van G, Genevieve C, Genevieve B, et al. Pharmaceutical pricing and reimbursement information-France[EB/OL]. [2012-01-28]. http:// ppri.oebig.at/downloads/result s/franee_ppri_2007 .pdf.
3International Society for Phannacoeconmics and Outcomes Research. The Netherlands-reimbursement process[EB/OL]. [2012-01-28]. http:// www.isoor.or./htaroadmaps/Netherlands.asp.
